Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials.
作者： Krzysztof Adamowicz , Jacek Jassem , Artur Katz , Everardo D. Saad
DOI: 10.1016/J.CTRV.2011.07.002
关键词:
摘要: Abstract Background Health-related quality of life (HRQOL) parameters are often used as end points in phase III trials advanced breast cancer. The frequency and correlates significant gains HRQOL have not been assessed. Methods To evaluate the contemporary role for assessment cancer, we searched PubMed main companion papers reporting results on systemic antineoplastic therapies published between 1/98 7/09 11 leading journals. Results search yielded 87 that enrolled a total 33,669 patients. was mentioned/reported paper 34 trials, reported one (a 35/87 = 40%), mentioned abstract 19/34 cases (56%). There no temporal trend two 6-year periods. Although formal statistical comparisons were 31/35 (89%), difference found only 4/31 (13%) always favoring experimental arm. Given small number studies with finding, could assess gain HRQOL. Conclusions is key indicators treatment benefit but this setting do appear to affect differentially.
elsevier.com
sci-hub.se 参考文章(58)
J Dancey, B Zee, D Osoba, M Whitehead, F Lu, L Kaizer, J Latreille, JL Pater, Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy Quality of Life Research. ,vol. 6, pp. 151- 158 ,(1997) , 10.1023/A:1026442201191
Anthony Howell, John Pippen, Richard M. Elledge, Louis Mauriac, Ignace Vergote, Stephen E. Jones, Steven E. Come, C. Kent Osborne, John F.R. Robertson, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma Cancer. ,vol. 104, pp. 236- 239 ,(2005) , 10.1002/CNCR.21163
B. Norris, K.I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, J. Latreille, L. Rudinskas, W. Lofters, M. Trudeau, D. Osoba, A. Rodgers, Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 Journal of Clinical Oncology. ,vol. 18, pp. 2385- 2394 ,(2000) , 10.1200/JCO.2000.18.12.2385
A. Buzdar, J. Douma, N. Davidson, R. Elledge, M. Morgan, R. Smith, L. Porter, J. Nabholtz, X. Xiang, C. Brady, Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate Journal of Clinical Oncology. ,vol. 19, pp. 3357- 3366 ,(2001) , 10.1200/JCO.2001.19.14.3357
J.-M. Nabholtz, H. J. Senn, W. R. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy Journal of Clinical Oncology. ,vol. 17, pp. 1413- 1424 ,(1999) , 10.1200/JCO.1999.17.5.1413
Jacek Jassem, Tadeusz Pieńkowski, Anna Płuzańska, Svetislav Jelic, Vera Gorbunova, Zrinka Mrsic-Krmpotic, Juris Berzins, Tomas Nagykalnai, Nelly Wigler, Josette Renard, Stephane Munier, Catherine Weil, Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial Journal of Clinical Oncology. ,vol. 19, pp. 1707- 1715 ,(2001) , 10.1200/JCO.2001.19.6.1707
James F. Bishop, Joanna Dewar, Guy C. Toner, Jennifer Smith, Martin H.N. Tattersall, Ian N. Olver, Stephen Ackland, Ian Kennedy, David Goldstein, Howard Gurney, Euan Walpole, John Levi, Jennifer Stephenson, Renzo Canetta, Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology. ,vol. 17, pp. 2355- 2364 ,(1999) , 10.1200/JCO.1999.17.8.2355
P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, H A Chaudri, U Hornberger, P F Trunet, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology. ,vol. 16, pp. 453- 461 ,(1998) , 10.1200/JCO.1998.16.2.453
R. Paridaens, L. Biganzoli, P. Bruning, J.G. M. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, A. Awada, J. Wildiers, M. Piccart, , Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer : a European organization for research and treatment of cancer randomized study with cross-over Journal of Clinical Oncology. ,vol. 18, pp. 724- 733 ,(2000) , 10.1200/JCO.2000.18.4.724
A Coates, V Gebski, D Signorini, P Murray, D McNeil, M Byrne, J F Forbes, Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology. ,vol. 10, pp. 1833- 1838 ,(1992) , 10.1200/JCO.1992.10.12.1833